非布司他联合非诺贝特治疗难治性痛风临床观察

Clinical observation of combined therapy consisting of Febuxostat and Fenofibrate on patients with refractory gout

目的观察非布司他联合非诺贝特治疗难治性痛风的疗效和安全性。方法选取42例难治性痛风患者,随机分为治疗组和对照组,治疗组给予非布司他联合非诺贝特治疗,对照组只给予非布司他治疗,2组均同时接受饮食指导和碱化尿液治疗。观察2组治疗前后血尿酸水平以及不良反应。结果经3个月治疗,2组患者血尿酸水平较治疗前均有显著下降(P<0.01);治疗后2组间血尿酸水平差异有显著性(P<0.01);治疗组血尿酸水平达标率高于对照组,组间比较差异显著(P<0.01);2组不良反应发生率差异无显著性(P>0.05)。结论非布司他联合非诺贝特治疗难治性痛风降尿酸效果优于单独使用非布司他,副作用无明显增加,值得推广。

Objective To observe the efficacy and safety of combined therapy consist of febuxostat andfenofibrate.Methods forty-two patients with infractory gout were randomly assigned into therapy group and controlgroup,the therapy group were treated with febuxostat combined with fenofibrate,the control group were treated withfebuxostat,the two group were given diet guidance and urine alkalization treatment.the serum uric acid level and sideeffects were observed.Results After three months’treatment,the serum uric acid levels in both group were significantlydecreased compared with those before treatment(P<0.01);Serum uric acid levels were significantly different between thetwo groups after treatment(P<0.01);the rate of reaching the standard in therapy group was very singnificanthigher thanthat in control group(P<0.01);the rate of adverse reactions had no significant differece(P>0.05).Conclusioncombination therapy of febuxostat and fenofibrate is better than only treat with febuxostatin reduce serum uric level,andthe side-effect has not increased signifantly,the combination therapy is a good method for patients with infractory gout.